These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 3931325

  • 1. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa.
    Heney NM.
    Urology; 1985 Oct; 26(4 Suppl):27-9. PubMed ID: 3931325
    [Abstract] [Full Text] [Related]

  • 2. Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.
    Koontz WW, Heney NM, Soloway MS, Kluskens L, Hazra TA, Trump DL, Barton B.
    Urology; 1985 Oct; 26(4 Suppl):30-1. PubMed ID: 3931326
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H, Benson RC, Hilton JF, Taylor WF.
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [Abstract] [Full Text] [Related]

  • 6. Intravesical chemotherapy: how effective is it?
    Heney NM.
    Urology; 1988 Mar; 31(3 Suppl):17-9. PubMed ID: 3126591
    [Abstract] [Full Text] [Related]

  • 7. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M, McGarry R, Kupelnick B.
    Anticancer Res; 2001 Mar; 21(1B):765-9. PubMed ID: 11299841
    [Abstract] [Full Text] [Related]

  • 8. Introduction and overview of intravesical therapy for superficial bladder cancer.
    Soloway MS.
    Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
    [Abstract] [Full Text] [Related]

  • 9. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 10. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R.
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [Abstract] [Full Text] [Related]

  • 11. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS, Chow NH, Lin JS, Yang WH, Tong YC.
    Anticancer Res; 1998 Mar; 18(6B):4717-21. PubMed ID: 9891547
    [Abstract] [Full Text] [Related]

  • 12. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H.
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [Abstract] [Full Text] [Related]

  • 13. [Mitomycin C for the treatment of superficial tumors of the bladder (Tis-Ta-T1) with one or more risk factors. Argentinian Cooperative Group of Oncourology (GCAO)].
    Villaronga A, Bellver E, Perli G, Pautaso O, Bengochea D, Roldán RA, Podskubska O, Belén R, Delgado G, Laberti O, Lando R, Rey H, Bengio R, Minuzzi L, Goldman E, Milman A, Sanguinetti O, Wernert O.
    Arch Esp Urol; 1996 Mar; 49(2):133-8. PubMed ID: 8702323
    [Abstract] [Full Text] [Related]

  • 14. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
    Huben RP.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
    [Abstract] [Full Text] [Related]

  • 15. Use of mitomycin as prophylaxis following endoscopic resection of superficial bladder cancer.
    Huland H, Otto U.
    Urology; 1985 Oct; 26(4 Suppl):32-5. PubMed ID: 4049627
    [Abstract] [Full Text] [Related]

  • 16. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
    Fisher HA.
    Prog Clin Biol Res; 1989 Oct; 310():275-83. PubMed ID: 2505271
    [No Abstract] [Full Text] [Related]

  • 17. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT, Yildirim U, Zorlu F, Ozen H.
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [Abstract] [Full Text] [Related]

  • 18. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
    Mobley WC, Loening SA, Narayana AS, Culp DA.
    Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
    [Abstract] [Full Text] [Related]

  • 19. Intravesical chemotherapy.
    Prout GR.
    Prog Clin Biol Res; 1984 Apr; 162B():125-50. PubMed ID: 6438639
    [No Abstract] [Full Text] [Related]

  • 20. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A, Bock PR.
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.